Life sciences cloud software provider Veeva Systems (NYSE: VEEV) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 16% year on year to $836 million. Guidance for next quarter’s revenue was better than expected at $856.5 million at the midpoint, 1% above analysts’ estimates. Its non-GAAP profit of $2.06 per share was 6.5% above analysts’ consensus estimates.

Is now the time to buy VEEV? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Veeva Systems delivered a positive fourth quarter, with results that exceeded Wall Street’s expectations and drove a significant share price reaction. Key contributors to the quarter’s performance included strong demand for modernizing legacy systems, especially in safety and R&D, and continued expansion in the customer base, particularly among top 20 pharmaceutical companies. CEO Peter Gassner emphasized that most demand stemmed from the need for scalable, automated core systems rather than direct AI adoption, stating, “The goal there is automation…AI is not the only way you do automation.” Management also credited robust execution in services and successful migrations to Vault CRM as important growth levers.

Looking ahead, Veeva’s guidance is shaped by expectations of continued healthy growth in its core businesses and the gradual integration of AI-driven features across its platform. Management highlighted that while AI is not yet a broad theme, customer interest is growing, especially for solutions that enable automation and compliance within life sciences workflows. CFO Brian Van Wagener noted, “This year is about rolling out agents in all of our product areas, getting customers live, refining the product, really creating a lot of value.” The company’s outlook is underpinned by cautious optimism as customers seek reliable partners for digital transformation, but management stressed the importance of execution as new R&D products and safety solutions continue to scale.

Key Insights from Management’s Remarks

Management attributed the quarter’s outperformance to strong demand for system modernization, robust execution in services, and successful growth in key product areas, with automation and expanded customer relationships playing central roles.

• Core system modernization demand: Management observed that many customers, particularly top 20 pharmaceutical firms, are seeking scalable, automated solutions to replace aging legacy infrastructure. Gassner explained that while AI is a factor, “more of the theme is…we need core systems that will scale,” with automation and deferred maintenance driving urgency.

• Vault CRM migration momentum: Paul Shawah, EVP Strategy, reported nearly 140 customers now live on Vault CRM, including several top 20 companies. These migrations have increased opportunities for cross-selling additional products like Network and OpenData, with Shawah noting, “as they went to Vault CRM, they expanded globally with Network and OpenData.”

• Service business execution: CFO Brian Van Wagener credited the professional services team for strong execution, especially in business consulting and R&D-related projects. Increased CRM migration activity contributed to higher services revenue and a profitable margin profile, trends expected to continue into the next year.

• Safety and AI integration progress: Veeva’s safety solutions recorded notable wins, including a top 20 pharmaceutical customer standardizing on RTSM (Randomization and Trial Supply Management). Management described a “safety surge,” with early AI agents targeting labor-intensive processes, such as case narrative generation, to reduce costs and improve compliance.

• Expansion in contract research organization (CRO) channel: Gassner detailed a new focus on leveraging CROs as a channel for study-by-study deals, particularly for emerging biotech customers. This strategy is expected to open new revenue streams as Veeva’s EDC (Electronic Data Capture), RTSM, and eCOA (electronic Clinical Outcome Assessment) products are increasingly bundled and offered through CRO partners.

Drivers of Future Performance

Veeva’s outlook is driven by continued product innovation, customer adoption of AI-powered features, and expansion into new channels and customer segments.

• AI-driven automation rollout: Management expects to expand its suite of AI agents across all product areas this year, aiming to streamline compliance, content creation, and workflow automation for life sciences customers. While initial financial contributions from these agents are expected to be modest, the foundation set in the past year positions Veeva for longer-term growth as adoption scales.

• Growth in R&D and safety solutions: The company anticipates that new R&D products, particularly in RTSM and LIMS (Laboratory Information Management Systems), and continued wins in safety will drive subscription growth. Management cautioned that as these newer offerings ramp up, growth may shift from mature products to these expanding segments, potentially influencing the pace of overall revenue growth.

• CRO channel and study-by-study deals: Veeva is placing greater emphasis on using contract research organizations to reach small and mid-sized biotechs for study-based sales of EDC, RTSM, and eCOA products. This channel presents a significant opportunity as more clinical trials are outsourced and as biotechs seek integrated technology solutions, though management indicated that realizing the full potential will take time.

Catalysts in Upcoming Quarters

Going forward, the StockStory team will closely watch (1) adoption rates and customer feedback on new AI agents across Veeva’s product portfolio, (2) the pace of migrations and cross-sell success in Vault CRM and R&D cloud products, and (3) traction in the CRO channel for study-by-study sales to biotechs. We will also monitor execution on safety and RTSM deployments, as well as any acceleration in customer wins among top 20 pharmaceutical companies.

Veeva Systems currently trades at $196.30, up from $188.19 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.